NYSEAM:YMI - Post Discussion
Post by
greatemailslob on Jan 20, 2010 10:04am
Dundee Securities
at the J.P. Morgan Healthcare Conference in San Francisco last week, Dundee Securities issued its latest biotech sector update.
On the bright side, analyst David Martin is also keeping an eye on YM Biosciences (TSX:YM (1.74 ?6.10%)) as the company expects to report results for four nimotuzumab trials this year, he says, adding that he is re-evaluating YM in light of the U.S. Treasury Department’s clearance for expanded nimotuzumab testing in the U.S., and YM’s recent acquisition of Cytopia
Be the first to comment on this post